Innate Pharma to Participate in Kempen Life Sciences Conference in April 2026

Innate Pharma S.A. (Nasdaq: IPHA), a clinical-stage biotechnology company focused on cancer immunotherapies, announced its participation in the upcoming Kempen Life Sciences Conference. The event is scheduled to take place from April 15 to April 16, 2026, in Amsterdam, Netherlands. Members of the company's executive team will be available for one-on-one investor meetings during the conference. The filing also highlights Innate Pharma's current clinical-stage portfolio, which includes IPH4502 (a Nectin-4 ADC for solid tumors), lacutamab (an anti-KIR3DL2 antibody for T-cell lymphomas), and monalizumab (an anti-NKG2A antibody being developed in collaboration with AstraZeneca for non-small cell lung cancer). The company continues to leverage its antibody-engineering expertise through strategic partnerships with industry leaders like Sanofi and AstraZeneca. No new clinical data or material financial updates were disclosed in this announcement.